Thoracic Cancer (Oct 2022)

Radial‐EBUS and virtual bronchoscopy planner for peripheral lung cancer diagnosis: How it became the first‐line endoscopic procedure

  • Samy Lachkar,
  • Loic Perrot,
  • Diane Gervereau,
  • Marielle De Marchi,
  • Helene Morisse Pradier,
  • Edouard Dantoing,
  • Nicolas Piton,
  • Luc Thiberville,
  • Florian Guisier,
  • Mathieu Salaün

DOI
https://doi.org/10.1111/1759-7714.14629
Journal volume & issue
Vol. 13, no. 20
pp. 2854 – 2860

Abstract

Read online

Abstract Background Various advanced bronchoscopy methods have been developed to reach peripheral lung lesions (PLL). In a large cohort, we aimed to assess a standardized procedure of first‐line radial‐endobronchial ultrasound (r‐EBUS) and virtual bronchoscopy planner for the diagnosis of peripheral lung cancer. Methods This retrospective, single center study included patients who had r‐EBUS‐guided bronchoscopy for the diagnosis of a PLL between 2008 and 2019. Cases without a final diagnosis of cancer or follow‐up were excluded. Results Between 2008 and 2019, 2735 patients had a r‐EBUS procedure, among whom 1627 had a final diagnosis of cancer and were included in the present study. Over the 12‐year study period, r‐EBUS became the first‐line endoscopic procedure to assess PLL (25% as first‐line bronchoscopy in 2008 vs. 92% in 2019). The frequency of the bronchus sign decreased from 2009 to 2019 (100% to 80%; p = 0.001), whereas US visualization of the lesion remained stable (88%). The median number of biopsies increased from two (2008 to 2014) to four (2015 to 2019) (p < 0.0001), with the same diagnostic efficiency (74% total and 80% when a bronchus sign was present). Of the 651 adenocarcinomas, molecular analysis was possible in 86%. PD‐L1 expression analysis was possible in 81% of cases. During the study period, the lifetime of the radial probe increased from 57 procedures to 77 procedures/probe. Conclusion Because r‐EBUS and VB planner is easy to perform under local anesthesia, inexpensive and efficient it can be used as a first‐line procedure to assess peripheral lung cancer.

Keywords